Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 129.50 GBp
Change Today -2.00 / -1.52%
Volume 61.9K
As of 11:30 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

summit therapeutics plc (SUMM) Snapshot

131.50 GBp
Previous Close
131.50 GBp
Day High
131.50 GBp
Day Low
128.50 GBp
52 Week High
03/2/15 - 185.00 GBp
52 Week Low
12/3/14 - 107.00 GBp
Market Cap
Average Volume 10 Days
-0.26 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

summit therapeutics plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit therapeutics plc (SUMM) Details

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company develops SMT C1100, an utrophin modulator that is in Phase Ib clinical study for the treatment of DMD; and SMT 19969, a novel antibiotic, which is in Phase II proof of concept clinical trial for the treatment of CDI. It has strategic alliance with the University of Oxford to develop the future generation utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

25 Employees
Last Reported Date: 05/7/15
Founded in 2003

summit therapeutics plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit therapeutics plc (SUMM) Key Developments

Summit Therapeutics plc - Special Call

To discuss the results of the Phase 2 clinical trial

Summit Therapeutics plc Announces Success of CoDIFy Phase 2 Clinical Trial for C. Difficile Infection

Summit Therapeutics plc announced the success of CoDIFy, a Phase 2 proof of concept clinical trial that evaluated the novel, oral antibiotic, ridinilazole (SMT19969) against the current standard of care, vancomycin, for the treatment of CDI. The Phase 2 trial exceeded its primary endpoint with ridinilazole achieving statistical superiority over vancomycin in sustained clinical response using the pre-specified 90% confidence interval, with SCR rates of 66.7% for ridinilazole compared to 42.4% for vancomycin. SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of treatment. The statistical superiority in SCR with ridinilazole in this trial was driven by a large numerical reduction in recurrent disease compared with vancomycin. CoDIFy was a double blind, randomized, active controlled, multicenter, Phase 2 clinical trial that evaluated the efficacy of ridinilazole against vancomycin in a total of 100 patients. Half of the patients received ridinilazole for ten days and the remaining half received vancomycin for ten days (125 mg, four times a day). The trial was conducted in the United States and Canada. The primary endpoint was non-inferiority of ridinilazole compared to vancomycin in SCR. The trial met its primary endpoint with ridinilazole achieving an SCR rate of 66.7% compared to 42.4% for vancomycin (non-inferiority margin of 15%, p=0.0004). This also represents statistical superiority of ridinilazole over vancomycin using the pre-specified 90% confidence interval. The primary analysis was conducted on the modified intent-to-treat ('mITT') population that comprised subjects with CDI confirmed by the presence of free toxin. Ridinilazole was generally well tolerated and the overall adverse event profiles of ridinilazole and vancomycin were comparable. More detailed findings from the trial will be reported at relevant conferences and in peer-reviewed journals.

Summit Therapeutics and University of Oxford Announce Multi-Year Extension of Strategic Alliance

Summit Therapeutics plc announced a multi-year extension of its strategic alliance with the University of Oxford until November 2019, with an option to extend it for a further 12 months, to support and accelerate development of future generation utrophin modulators for the treatment of the progressive muscle wasting disorder, DMD. Under the terms of the alliance extension, Summit retains an exclusive option to arising intellectual property (IP) in the field of utrophin modulation generated during the term of the collaboration. Summit will also continue to sponsor a drug discovery and development programme in the University of Oxford research laboratories to identify and develop oral utrophin modulators for the treatment of DMD. This research programme, originally running to November 2016, will now continue until November 2019 with an option to extend it for a further 12 months. As part of the extension, Summit will increase the funding to £0.83 million a year starting in November 2015. Isis Innovation Limited (Isis) continues to hold warrants over 354,090 ordinary shares that were granted as part of the original alliance agreement signed in 2013. All the warrants may be exercised by Isis by February 2020, three months after the end of the alliance extension, subject to achieving key research, development and regulatory milestones.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 129.50 GBp -2.00

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SUMMIT THERAPEUTICS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at